

HALF-YEAR INVESTOR CONFERENCE CALL – UPDATED DIAL IN DETAILS

Acrux (ASX: ACR) advises of changed dial-in phone numbers provided by its conference call service provider. Below are the updated details for the conference call to discuss the results for the half-year ended 31 December 2016.

Investor Conference Call details:

Date: **Tuesday 21 February 2017**

Time: **10:00am (AEDT)**

Conference ID: 5034 5465

Dial-in phone numbers:

Australia toll free phone number: 1800 123 296

Australia: +61 2 8038 5221

New Zealand: 0800 452 782

Singapore: 800 616 2288

United States: 1855 293 1544

United Kingdom: 0808 234 0757

A Q&A session will be held following the Company presentation. Shareholders and analysts are encouraged to participate by forwarding questions to investor@acrux.com.au in advance of the conference call.

Acrux recommends participants dial in prior to the commencement of the call. A recording of the call will be made available in the 'Investor Centre' section of the Company website at: <http://www.acrux.com.au/>

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

Tim Bateman, CFO and Company Secretary: 03 8379 0100



About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron®, Evamist® and Lenzetto®. More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au

